Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases
-- Combined company to assume the name, Lumos Pharma, Inc. and is expected to be led by Richard J. Hawkins , current CEO of Lumos Pharma -- -- Lumos asset, LUM-201, represents first oral therapeutic candidate for pediatric growth hormone deficiency (PGHD) with planned Phase 2b expected to begin in
View HTML
Toggle Summary NewLink Genetics Announces FDA Accepts Partnered Biologics License Application (BLA) and Grants Priority Review for Ebola Vaccine V920 (rVSV∆G-ZEBOV-GP)
AMES, Iowa , Sept. 17, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted Merck’s Biologics License Application (BLA) and granted priority review for the investigational Ebola vaccine (V920), for the
View HTML
Toggle Summary NewLink Genetics Provides Corporate Update and Reports Second Quarter 2019 Financial Results
Announces management transition; Charles J. Link Jr, M.D. to retire as CEO and Chairman of the Board AMES, Iowa , July 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink Genetics” or the “Company”) today announced financial results for the second quarter ended June
View HTML
Toggle Summary NewLink Genetics Presents Updated NLG802 Results at the Immuno-Oncology 2019 World Congress
NLG802 , a prodrug of indoximod, produced significantly higher pharmacokinetic (PK) exposure in patients compared to molar equivalent of indoximod while maintaining encouraging safety profile Notable response in 5 th line pancreatic cancer patient re-challenged with chemotherapy after NLG802
View HTML
Toggle Summary NewLink Genetics Reports First Quarter 2019 Financial Results and Provides Clinical Activities Update
- Management to host conference call today at 4:30 p.m. ET AMES, Iowa , May 08, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the first quarter ended March 31, 2019 and provided an update on clinical activities.
View HTML
Toggle Summary NewLink Genetics to Participate in Upcoming Investor and Medical Conferences
AMES, Iowa , May 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor and medical conferences: Bank of America Merrill Lynch Global Health Care Conference 2019 on May 14-16 in Las Vegas Management will
View HTML
Toggle Summary NewLink Genetics to Host Its First Quarter 2019 Conference Call on May 8, 2019
AMES, Iowa , April 24, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will host its first quarter 2019 conference call and webcast at 4:30 PM ET on Wednesday, May 8, 2019, to discuss its first quarter financial results and provide an update of its clinical
View HTML
Toggle Summary NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
AMES, Iowa, April 02, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced results from a Phase 2 study of NLG207 , a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin, conducted in conjunction with The GOG Foundation, Inc.
View HTML
Toggle Summary NewLink Genetics Announces Clinical Trial Abstract Presentation at AACR Annual Meeting
AMES, Iowa , Feb. 27, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that a late-breaking abstract reporting results from a Phase 2 study of NLG207 , a nanoparticle formulation of the topoisomerase 1 inhibitor, camptothecin, has been accepted for poster
View HTML
Toggle Summary NewLink Genetics Reports Fourth Quarter, Year-End 2018 Financial Results and Provides Update for Clinical Programs
Management to Host Conference Call Today at 4:30 p.m. ET AMES, Iowa , Feb. 27, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) today reported consolidated financial results for the fourth quarter and year ended 2018, as well as progress in its clinical development programs. The
View HTML